Perhaps some disappointment around the EBITDA guidance, but the results commentary did suggest a stronger than expected NPAT in H2 2024 due to cost cutting. I guess the proof will be in the pudding. Initially I was pleased by the ex covid testing revenue growth (even accounting for acquisitions), but looking at the even stronger growth in costs, this put a bit of a dampener on it. As you said, no franking credit on dividend.
SHL Price at posting:
$31.71 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)